Figure 1.
Uveitis in pooled secukinumab ankylosing spondylitis (AS) clinical trials. Rates reported are n (%) for the entire treatment period (N = 794) for preferred terms by using the Medical Dictionary for Regulatory Activities. aIncludes two cases of treatment discontinuation and one case of treatment interruption.